BennettDE, CamachoRJ, OteleaDet al.Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 2009; 4:e4724.
2.
JohnsonVA, Brun-VezinetF, ClotetBet al.Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med, 2010; 18:156–163.
3.
VianiRM, PeraltaL, AldrovandiGet al.Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis, 2006; 194:1505–1509.
4.
AmmaranondP, CunninghamP, OelrichsRet al.Rates of transmission of antiretroviral drug resistant strains of HIV-1. J Clin Virol, 2003; 26:153–161.
5.
TossonianHK, RaffaJD, GrebelyJet al.Primary drug resistance in antiretroviral-naive injection drug users. Int J Infect Dis, 2009; 13:577–583.
6.
MellinsCA, TassiopoulosK, MaleeKet al.Behavioral health risks in perinatally HIV-exposed youth: Co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDs, 2011; 25:413–422.
7.
Hightow-WeidmanLB, HurtCBet al.Transmitted HIV-1 drug resistance among young men of color who have sex with men: A multicenter cohort analysis. J Adolesc Health, 2011; 48:94–99.
8.
MitschA, HuX, McDavid HarrisonK, DurantT. Division of HIV/AIDS Prevention, National Center for HIV AIDS Viral Hepatitis STD and TB Prevention CDC. Trends in HIV/AIDS diagnoses among men who have sex with men—33 states, 2001–2006, 2008May17, 2010.
9.
GoldsamtLA, ClattsMC, ParkerMM, ColonV, HallackR, MessinaMG. Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City. AIDS Patient Care STDs, 2011; 25:287–293.
10.
HurtCB, MatthewsDD, CalabriaMSet al.Sex with older partners is associated with primary HIV infection among men who have sex with men in North Carolina. J Acquir Immune Defic Syndr, 2010; 54:185–190.
11.
Leigh BrownAJ, FrostSD, MathewsWCet al.Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis, 2003; 187:683–686.
12.
RudyBJ, KapogiannisBG, LallyMAet al.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr, 2010; 54,Suppl 1:S31–S42.